Abner Herrman & Brock Sours on Intuitive Surgical

Abner Herrman & Brock LLC (AHB) reduced its stake in Intuitive Surgical (ISRG) during Q3 2025, selling 9,629 shares valued at approximately $4.62 million, bringing its holding to 1.01% of AUM. This divestment followed a period of underperformance for ISRG shares and coincided with AHB paring other healthcare technology holdings while increasing exposure to major tech companies, suggesting a potential portfolio reallocation. Notably, this reduction occurred prior to Intuitive Surgical's strong Q3 earnings report, which exceeded analyst expectations.

Analysis

Abner Herrman & Brock (AHB) significantly reduced its stake in Intuitive Surgical (ISRG) during Q3 2025, divesting 9,629 shares valued at approximately $4.62 million. This reduction occurred while ISRG shares were underperforming, down 10.6% year-over-year and 10% in Q3 due to tariff concerns and competitive pressures. AHB's remaining position in ISRG now constitutes 1.01% of its AUM, placing it outside the fund's top five holdings.

The divestment from ISRG aligns with AHB's broader portfolio adjustments, which included paring positions in other healthcare technology companies like Stryker and Abbott Laboratories. Concurrently, AHB increased its exposure to major technology firms such as Nvidia, Microsoft, Amazon, and Tesla. This indicates a potential strategic reallocation of capital away from healthcare tech towards large-cap growth technology.

Notably, AHB's Q3 2025 sale of ISRG shares preceded the company's robust Q3 earnings report. Intuitive Surgical subsequently beat analyst expectations on both revenue and earnings, reporting a 20% year-over-year increase in worldwide procedures and strong demand for its da Vinci 5 model. This suggests AHB's decision was based on prior market conditions rather than the company's later-revealed fundamental strength.

Key Decisions for Investors

• Evaluate Intuitive Surgical's recent strong Q3 earnings, including 20% procedure growth and da Vinci 5 demand, as a potential indicator of fundamental strength despite prior share underperformance.
• Consider Abner Herrman & Brock's portfolio reallocation as a potential sector rotation signal, noting their reduced exposure to healthcare technology and increased allocation to big tech.
• Monitor future institutional filings to assess if other major funds are similarly adjusting their healthcare technology exposure, which could indicate a broader industry trend.